ethyl 2-acetamido-2-deoxy-4-O-(4-O-α-D-galactopyranosyl-β-D-galactopyranosyl)-β-D-glucopyranoside | 90232-54-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 2-acetamido-2-deoxy-4-O-(4-O-α-D-galactopyranosyl-β-D-galactopyranosyl)-β-D-glucopyranoside
• 英文别名: alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc-OEt；N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-ethoxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• CAS: 90232-54-5
• 化学式: C₂₂H₃₉NO₁₆
• 分子量: 573.549
• InChiKey: CILUQAXPWNXAQT-BBFYYQRMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  267
• 氢给体数：
  10
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  ethyl 2-acetamido-3,6-di-O-benzyl-2-deoxy-4-O-<2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-β-D-galactopyranosyl>-β-D-glucopyranoside 在 palladium on activated charcoal 氢气 、 sodium methylate 作用下， 以 溶剂黄146 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 26.5h， 生成 ethyl 2-acetamido-2-deoxy-4-O-(4-O-α-D-galactopyranosyl-β-D-galactopyranosyl)-β-D-glucopyranoside
  参考文献：
  名称：

  血液末端三糖[α-d-Gal-（1→4）-β-d-Gal-（1→4）-β-d-GlcNAc]部分的间隔臂，脂质和乙基糖苷的合成-P1抗原：新糖蛋白的制备

  摘要：

  摘要通过α-d-Gal-（1→4）-β-d-Gal-（1→4）-β-d-GlcNAc的乙酰化2-溴乙基β-糖苷（5）制备标题化合物分别与3-巯基丙酸甲酯，十八烷硫醇和氢形成溴离子。三氟甲磺酸银促进的2,3,6-三-O-乙酰基-4-O-（2-溴乙基3,6-二-O-苄基-2-脱氧-2-邻苯二甲酰亚胺-β-d-吡喃葡萄糖苷的糖基化作用2,3,4,6-四-O-乙酰基-α-d-半乳糖吡喃糖基）-α-d-半乳糖基吡喃糖基溴得到5。将衍生自3-巯基丙酸甲酯的间隔臂糖苷与牛血清白蛋白和匙孔血蓝蛋白偶联，得到新糖蛋白。

  DOI：

  10.1016/0008-6215(84)85299-4

文献信息

• Glycosides
  申请人：Svenska Sockerfabriks AB

  公开号：US04675392A1

  公开（公告）日：1987-06-23

  An O-glycoside having the general formula: (sugar).sub.n --O--(CH.sub.2).sub.m --Hal wherein Hal is chlorine, bromine or iodine, m is an integer of 2-20 inclusive and n is an integer of 1 to 10, inclusive, with the proviso that when n=1 and m=2, the aldose is different from glucose; An O-glycoside having the general formula: (sugar).sub.n --O--(CH.sub.2).sub.m --S--R--R' wherein n is an integer of from 1-10, inclusive, m is an integer of from 2-20, inclusive, R is selected from the group consisting of alkyl having at most 25 carbon atoms and aryl and R' is selected from the group consisting of H, CHO, CH(OR').sub.2, NO.sub.2, NH.sub.2, OH, SH, COOH, COOCH.sub.3, COOCH.sub.2 CH.sub.3, CONHNH.sub.2 and CON.sub.3, wherein R" is C.sub.1-4 -alkyl; A glycoconjugate having the general formula: (sugar).sub.n --O--(CH.sub.2).sub.m --S--R--R" wherein n is an integer of from 1-10, inclusive, m is an integer of from 2-20, inclusive, R is selected from the group consisting of alkyl having at most 25 carbon atoms and aryl and R" constitutes a carrier; A bi-dentate O-glycoside having the general formula: [(sugar).sub.n --O--(CH.sub.2).sub.m --S--.sub.2 R wherein m, n and R have the above meaning; and processes for their preparation.

  一种具有一般式的O-糖苷：(糖).sub.n --O--(CH.sub.2).sub.m --Hal，其中Hal为氯、溴或碘，m为2-20的整数，n为1-10的整数，但当n=1且m=2时，醛糖与葡萄糖不同；一种具有一般式的O-糖苷：(糖).sub.n --O--(CH.sub.2).sub.m --S--R--R'，其中n为1-10的整数，m为2-20的整数，R选自最多具有25个碳原子的烷基和芳基，R'选自H、CHO、CH(OR').sub.2、NO.sub.2、NH.sub.2、OH、SH、COOH、COOCH.sub.3、COOCH.sub.2 CH.sub.3、CONHNH.sub.2和CON.sub.3的群，其中R"为C.sub.1-4-烷基；一种具有一般式的糖基结合物：(糖).sub.n --O--(CH.sub.2).sub.m --S--R--R"，其中n为1-10的整数，m为2-20的整数，R选自最多具有25个碳原子的烷基和芳基，R"构成载体；一种具有一般式的双叉O-糖苷：[(糖).sub.n --O--(CH.sub.2).sub.m --S--.sub.2R其中m，n和R具有上述含义；以及它们的制备过程。
• Präparat zur Wirkstoffapplikation in Kleinsttröpfchenform
  申请人：Cevc, Gregor, Prof. Dr.

  公开号：EP0475160A1

  公开（公告）日：1992-03-18

  Die Erfindung betrifft ein Präparat zur Applikation von Wirkstoffen in Form kleinster, insbesondere mit einer membranartigen Hülle aus einer oder wenigen Lagen amphiphiler Moleküle bzw. mit einer amphiphilen Trägersubstanz versehenen Flüssigkeitströpfchen, insbesondere zum Transport des Wirkstoffes in und durch natürliche Barrieren und Konstriktionen wie Häute und dergleichen. Das Präparat weist einen Gehalt einer randaktiven Substanz auf, der bis zu 99 Mol.-% des Gehaltes dieser Substanz entspricht, durch den der Solubilisierungspunkt der Tröpfchen erreicht wird. Das Präparat eignet sich zur nichtinvasiven Verabreichung von Antidiabetica, insbesondere von Insulin. Die Erfindung betrifft außerdem ein Verfahren zur Herstellung solcher Präparate.

  本发明涉及一种以微小液滴形式施用活性物质的制剂，特别是具有一层或几层两亲性分子或两亲性载体物质的膜状包膜，尤其是用于将活性物质输送到或通过皮肤等天然屏障和收缩物。制剂中边缘活性物质的含量最高可达 99 摩尔%，从而达到液滴的溶解点。该制剂适用于非侵入性给药抗糖尿病药物，特别是胰岛素。本发明还涉及生产这种制剂的工艺。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。
• New and novel glycosides, glycoconjugates and processes for their preparation
  申请人：BIOCARB AB

  公开号：EP0098252B1

  公开（公告）日：1989-06-07
• Preparation for the application of agents in mini-droplets
  申请人：Cevc Gregor

  公开号：US20070042030A1

  公开（公告）日：2007-02-22

  The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.